Titlebook: Managing Gout in Primary Care; Fernando Perez-Ruiz,Ana Maria Herrero-Beites Book 2014 Springer Healthcare 2014 Gout; rheumatology; primary

endocarditis

書目名稱Managing Gout in Primary Care影響因子(影響力)




書目名稱Managing Gout in Primary Care影響因子(影響力)學科排名




書目名稱Managing Gout in Primary Care網(wǎng)絡(luò)公開度




書目名稱Managing Gout in Primary Care網(wǎng)絡(luò)公開度學科排名




書目名稱Managing Gout in Primary Care被引頻次




書目名稱Managing Gout in Primary Care被引頻次學科排名




書目名稱Managing Gout in Primary Care年度引用




書目名稱Managing Gout in Primary Care年度引用學科排名




書目名稱Managing Gout in Primary Care讀者反饋




書目名稱Managing Gout in Primary Care讀者反饋學科排名

BOOM

Treatment of Hyperuricemia in Gout,reducing the risk of episodes of acute inflammation (EAIs) that appear and even increase in frequency during the initiation of ULT (prophylaxis); (3) promptly, safely, and effectively treating any EAIs that may appear until proper and stable serum urate levels are achieved.

幸福愉悅感

orthopedist

Physiopathology of gout,nd genetic or acquired tissue predisposition for the nucleation of MSUCs, may explain why not all patients with hyperuricemia develop gout, or why some patients develop early or rapidly progressive symptoms associated with gout.

Credence

daredevil

Book 2014ood-quality evidence on gout impact and management has grown exponentially, renal transporters have been recently identified, and a number of new drugs have been approved or are under current development.

異端邪說2

無目標

Physiopathology of gout,vial fluid or cause aggregate-inducing chronic tissue inflammation. The nucleation and formation of MSUCs is related to the presence of longstanding hyperuricemia, which is an essential factor in the development of gout. Other factors, such as level of hyperuricemia, time exposed to hyperuricemia, a

BLOT

迅速成長

Treatment of Hyperuricemia in Gout,urate to the therapeutic range to dissolve monosodium urate crystals (MSUCs) formed in tissues, using urate-lowering therapy (ULT); (2) preventing or reducing the risk of episodes of acute inflammation (EAIs) that appear and even increase in frequency during the initiation of ULT (prophylaxis); (3)